A Vaccine Approach To Treating Parkinson's Disease

[Guest guest]

http://www.medi-news.com/article2427.html

A Vaccine Approach To Treating Parkinson's Disease

Researchers at the UCSD School of Medicine working with scientists at Elan

Pharmaceuticals, have reported promising results in mice of a vaccine

approach to treating Parkinson’s and similar diseases. These results appear

in the June edition of the journal Neuron.

Dr. Eliezer Masliah, Professor of Neurosciences and Pathology at UCSD, and

colleagues at UCSD and Elan Pharmaceuticals in San Francisco, vaccinated

mice using a a combination of the protein that abnormally accumulates in the

brains of Parkinson’s (called human alpha-synuclein) and an adjuvant. This

approach resulted in the generation of anti-alpha synuclein antibodies in

mice that are specially bred by Masliah’s team to simulate Parkinson’s

disease, resulting in reduced build-up of abnormal alpha-synuclein. The

accumulation of abnormal alpha-synuclein is associated with degeneration of

nerve cells and interference with normal inter-cellular communication,

leading to Parkinson’s disease and dementia.

The work marks the first time a vaccine for this family of diseases has been

found effective in animal studies. Scientists at Elan Pharmaceuticals have

been working for the past few years in a vaccine for Alzheimer’s Disease.

The researchers focused on a spectrum of neurological disorders called Lewy

body disease, which include Parkinson’s and Alzheimer’s. These disorders are

marked by the presence of Lewy bodies -- abnormal clumps of

alpha-synuclein -- in the brain. Normally, alpha-synuclein proteins support

communications between brain cells, or neurons. However, when abnormal

proteins clump together in the neurons, a build-up of synuclein can cut off

neuron activity, blocking normal signaling between brain cells and

ultimately choking the cells to death.

“We found that the antibodies produced by the vaccinated mice recognized and

reduced only the abnormal form of alpha-synuclein, since the protein’s

normal form is in a cellular compartment where antibodies can’t reach it,”

said Masliah. “Abnormal alpha-synuclein finds its way to the cell membrane,

where antibodies can recognize it.”

Masliah stressed that the team’s experimental active immunization, while

effective in mice, may not be as useful in humans. “We would not want to

actively immunize humans in this way by triggering antibody development,

because one could create harmful inflammation,” he cautioned. “However, it

might be feasible to inject antibodies directly, as if the patient were

creating his or her own.”

The team, the first to identify the presence of these proteins in the human

brain, originally thought the protein played an important role in the

development of Alzheimer’s disease. Then, an explosion of research linked

Lewy bodies and their constituent proteins to both Alzheimer’s and Parkinson

’s. The team spent four years clarifying alpha-synuclein’s role in Parkinson

’s, developing a mouse model that contained the faulty and normal genes for

alpha-synuclein, and conducting the experiments that led to their current

findings.

With evidence that this approach could be effective in treating Lewy Body

disease, the UCSD researchers are now working with Elan Pharmaceuticals to

develop alternative ways to produce alpha-synuclein antibodies, with the

goal of making a vaccine that is safe and effective in humans. While this

research could take many years and holds no promise of prevention or cure,

the researchers are hopeful that the mouse studies are a step in the right

direction.

“This shows the first demonstration of a vaccine for this family of

disease,” Masliah said.

Co-authors of the paper are Rockenstein, Adame,

Alford, Crews and Makoto Hashimoto, at UCSD, and Seubert,

Lee, Goldstein, Tamie Chilcote, Dora Games, and Dale Schenk,

at Elan.

The research was supported by grants from Elan and the National Institute of

Aging.

Source: UCSD

[Guest guest]

I have a friend with early adult onset parkinson's - she is 38 yrs

old. Does homeopathy treat parkinson's?

~~ Jacqui

On 6/17/05, Mum2mishka <mum2mishka@...> wrote:

> http://www.medi-news.com/article2427.html

>

> A Vaccine Approach To Treating Parkinson's Disease

>

> Researchers at the UCSD School of Medicine working with scientists at Elan

> Pharmaceuticals, have reported promising results in mice of a vaccine

> approach to treating Parkinson's and similar diseases. These results appear

> in the June edition of the journal Neuron.

>

> Dr. Eliezer Masliah, Professor of Neurosciences and Pathology at UCSD, and

> colleagues at UCSD and Elan Pharmaceuticals in San Francisco, vaccinated

> mice using a a combination of the protein that abnormally accumulates in the

> brains of Parkinson's (called human alpha-synuclein) and an adjuvant. This

> approach resulted in the generation of anti-alpha synuclein antibodies in

> mice that are specially bred by Masliah's team to simulate Parkinson's

> disease, resulting in reduced build-up of abnormal alpha-synuclein. The

> accumulation of abnormal alpha-synuclein is associated with degeneration of

> nerve cells and interference with normal inter-cellular communication,

> leading to Parkinson's disease and dementia.

>

> The work marks the first time a vaccine for this family of diseases has been

> found effective in animal studies. Scientists at Elan Pharmaceuticals have

> been working for the past few years in a vaccine for Alzheimer's Disease.

>

> The researchers focused on a spectrum of neurological disorders called Lewy

> body disease, which include Parkinson's and Alzheimer's. These disorders are

> marked by the presence of Lewy bodies -- abnormal clumps of

> alpha-synuclein -- in the brain. Normally, alpha-synuclein proteins support

> communications between brain cells, or neurons. However, when abnormal

> proteins clump together in the neurons, a build-up of synuclein can cut off

> neuron activity, blocking normal signaling between brain cells and

> ultimately choking the cells to death.

>

> " We found that the antibodies produced by the vaccinated mice recognized and

> reduced only the abnormal form of alpha-synuclein, since the protein's

> normal form is in a cellular compartment where antibodies can't reach it, "

> said Masliah. " Abnormal alpha-synuclein finds its way to the cell membrane,

> where antibodies can recognize it. "

>

> Masliah stressed that the team's experimental active immunization, while

> effective in mice, may not be as useful in humans. " We would not want to

> actively immunize humans in this way by triggering antibody development,

> because one could create harmful inflammation, " he cautioned. " However, it

> might be feasible to inject antibodies directly, as if the patient were

> creating his or her own. "

>

> The team, the first to identify the presence of these proteins in the human

> brain, originally thought the protein played an important role in the

> development of Alzheimer's disease. Then, an explosion of research linked

> Lewy bodies and their constituent proteins to both Alzheimer's and Parkinson

> 's. The team spent four years clarifying alpha-synuclein's role in Parkinson

> 's, developing a mouse model that contained the faulty and normal genes for

> alpha-synuclein, and conducting the experiments that led to their current

> findings.

>

> With evidence that this approach could be effective in treating Lewy Body

> disease, the UCSD researchers are now working with Elan Pharmaceuticals to

> develop alternative ways to produce alpha-synuclein antibodies, with the

> goal of making a vaccine that is safe and effective in humans. While this

> research could take many years and holds no promise of prevention or cure,

> the researchers are hopeful that the mouse studies are a step in the right

> direction.

>

> " This shows the first demonstration of a vaccine for this family of

> disease, " Masliah said.

>

> Co-authors of the paper are Rockenstein, Adame,

> Alford, Crews and Makoto Hashimoto, at UCSD, and Seubert,

> Lee, Goldstein, Tamie Chilcote, Dora Games, and Dale Schenk,

> at Elan.

>

> The research was supported by grants from Elan and the National Institute of

> Aging.

>

> Source: UCSD

>

>

> ________________________________

>

[Guest guest]

Yes, homeopathy treats the whole person and all of their symptoms including

Parkinson's

Some drugs cause parkinson's like symptoms and also coffee

At 08:48 AM 6/18/2005 -0400, you wrote:

>I have a friend with early adult onset parkinson's - she is 38 yrs

>old. Does homeopathy treat parkinson's?

>

>~~ Jacqui

>

>

>

>On 6/17/05, Mum2mishka <mum2mishka@...> wrote:

>> http://www.medi-news.com/article2427.html

>>

>> A Vaccine Approach To Treating Parkinson's Disease

>>

>> Researchers at the UCSD School of Medicine working with scientists at Elan

>> Pharmaceuticals, have reported promising results in mice of a vaccine

>> approach to treating Parkinson's and similar diseases. These results appear

>> in the June edition of the journal Neuron.

>>

>> Dr. Eliezer Masliah, Professor of Neurosciences and Pathology at UCSD, and

>> colleagues at UCSD and Elan Pharmaceuticals in San Francisco, vaccinated

>> mice using a a combination of the protein that abnormally accumulates in

the

>> brains of Parkinson's (called human alpha-synuclein) and an adjuvant. This

>> approach resulted in the generation of anti-alpha synuclein antibodies in

>> mice that are specially bred by Masliah's team to simulate Parkinson's

>> disease, resulting in reduced build-up of abnormal alpha-synuclein. The

>> accumulation of abnormal alpha-synuclein is associated with degeneration of

>> nerve cells and interference with normal inter-cellular communication,

>> leading to Parkinson's disease and dementia.

>>

>> The work marks the first time a vaccine for this family of diseases has

been

>> found effective in animal studies. Scientists at Elan Pharmaceuticals have

>> been working for the past few years in a vaccine for Alzheimer's Disease.

>>

>> The researchers focused on a spectrum of neurological disorders called Lewy

>> body disease, which include Parkinson's and Alzheimer's. These disorders

are

>> marked by the presence of Lewy bodies -- abnormal clumps of

>> alpha-synuclein -- in the brain. Normally, alpha-synuclein proteins support

>> communications between brain cells, or neurons. However, when abnormal

>> proteins clump together in the neurons, a build-up of synuclein can cut off

>> neuron activity, blocking normal signaling between brain cells and

>> ultimately choking the cells to death.

>>

>> " We found that the antibodies produced by the vaccinated mice recognized

and

>> reduced only the abnormal form of alpha-synuclein, since the protein's

>> normal form is in a cellular compartment where antibodies can't reach it, "

>> said Masliah. " Abnormal alpha-synuclein finds its way to the cell membrane,

>> where antibodies can recognize it. "

>>

>> Masliah stressed that the team's experimental active immunization, while

>> effective in mice, may not be as useful in humans. " We would not want to

>> actively immunize humans in this way by triggering antibody development,

>> because one could create harmful inflammation, " he cautioned. " However, it

>> might be feasible to inject antibodies directly, as if the patient were

>> creating his or her own. "

>>

>> The team, the first to identify the presence of these proteins in the human

>> brain, originally thought the protein played an important role in the

>> development of Alzheimer's disease. Then, an explosion of research linked

>> Lewy bodies and their constituent proteins to both Alzheimer's and

Parkinson

>> 's. The team spent four years clarifying alpha-synuclein's role in

Parkinson

>> 's, developing a mouse model that contained the faulty and normal genes for

>> alpha-synuclein, and conducting the experiments that led to their current

>> findings.

>>

>> With evidence that this approach could be effective in treating Lewy Body

>> disease, the UCSD researchers are now working with Elan Pharmaceuticals to

>> develop alternative ways to produce alpha-synuclein antibodies, with the

>> goal of making a vaccine that is safe and effective in humans. While this

>> research could take many years and holds no promise of prevention or cure,

>> the researchers are hopeful that the mouse studies are a step in the right

>> direction.

>>

>> " This shows the first demonstration of a vaccine for this family of

>> disease, " Masliah said.

>>

>> Co-authors of the paper are Rockenstein, Adame,

>> Alford, Crews and Makoto Hashimoto, at UCSD, and Seubert,

>> Lee, Goldstein, Tamie Chilcote, Dora Games, and Dale Schenk,

>> at Elan.

>>

>> The research was supported by grants from Elan and the National

Institute of

>> Aging.

>>

>> Source: UCSD

>>

>>

>> ________________________________

>>

[Guest guest]

I know a trace elements scientist here in South Wales who urged a

Parkinsons's patient to take 200 micrograms of Selenium every day. The

symptoms reduced enormously. This is consistent with what I have been

reading about low glutathione (an anti-oxidant) in Parkinson's . Selenium is

the precursor to Glutathione.

Since glutathione is sulphur dependent, one has to explore the possiblity of

mercury poisoning as mercury binds to sulphur and reduces it's

bioavailabity.

Also Rotenone a so-called friendly pesticide which is used in

organicgardening is common to sufferers.

Re: A Vaccine Approach To Treating Parkinson's

Disease

> Yes, homeopathy treats the whole person and all of their symptoms

> including

> Parkinson's

> Some drugs cause parkinson's like symptoms and also coffee

>

> At 08:48 AM 6/18/2005 -0400, you wrote:

>>I have a friend with early adult onset parkinson's - she is 38 yrs

>>old. Does homeopathy treat parkinson's?

>>

>>~~ Jacqui

>>

>>

>>

>>On 6/17/05, Mum2mishka <mum2mishka@...> wrote:

>>> http://www.medi-news.com/article2427.html

>>>

>>> A Vaccine Approach To Treating Parkinson's Disease

>>>

>>> Researchers at the UCSD School of Medicine working with scientists at

>>> Elan

>>> Pharmaceuticals, have reported promising results in mice of a vaccine

>>> approach to treating Parkinson's and similar diseases. These results

>>> appear

>>> in the June edition of the journal Neuron.

>>>

>>> Dr. Eliezer Masliah, Professor of Neurosciences and Pathology at UCSD,

>>> and

>>> colleagues at UCSD and Elan Pharmaceuticals in San Francisco, vaccinated

>>> mice using a a combination of the protein that abnormally accumulates in

> the

>>> brains of Parkinson's (called human alpha-synuclein) and an adjuvant.

>>> This

>>> approach resulted in the generation of anti-alpha synuclein antibodies

>>> in

>>> mice that are specially bred by Masliah's team to simulate Parkinson's

>>> disease, resulting in reduced build-up of abnormal alpha-synuclein. The

>>> accumulation of abnormal alpha-synuclein is associated with degeneration

>>> of

>>> nerve cells and interference with normal inter-cellular communication,

>>> leading to Parkinson's disease and dementia.

>>>

>>> The work marks the first time a vaccine for this family of diseases has

> been

>>> found effective in animal studies. Scientists at Elan Pharmaceuticals

>>> have

>>> been working for the past few years in a vaccine for Alzheimer's

>>> Disease.

>>>

>>> The researchers focused on a spectrum of neurological disorders called

>>> Lewy

>>> body disease, which include Parkinson's and Alzheimer's. These disorders

> are

>>> marked by the presence of Lewy bodies -- abnormal clumps of

>>> alpha-synuclein -- in the brain. Normally, alpha-synuclein proteins

>>> support

>>> communications between brain cells, or neurons. However, when abnormal

>>> proteins clump together in the neurons, a build-up of synuclein can cut

>>> off

>>> neuron activity, blocking normal signaling between brain cells and

>>> ultimately choking the cells to death.

>>>

>>> " We found that the antibodies produced by the vaccinated mice recognized

> and

>>> reduced only the abnormal form of alpha-synuclein, since the protein's

>>> normal form is in a cellular compartment where antibodies can't reach

>>> it, "

>>> said Masliah. " Abnormal alpha-synuclein finds its way to the cell

>>> membrane,

>>> where antibodies can recognize it. "

>>>

>>> Masliah stressed that the team's experimental active immunization, while

>>> effective in mice, may not be as useful in humans. " We would not want to

>>> actively immunize humans in this way by triggering antibody development,

>>> because one could create harmful inflammation, " he cautioned. " However,

>>> it

>>> might be feasible to inject antibodies directly, as if the patient were

>>> creating his or her own. "

>>>

>>> The team, the first to identify the presence of these proteins in the

>>> human

>>> brain, originally thought the protein played an important role in the

>>> development of Alzheimer's disease. Then, an explosion of research

>>> linked

>>> Lewy bodies and their constituent proteins to both Alzheimer's and

> Parkinson

>>> 's. The team spent four years clarifying alpha-synuclein's role in

> Parkinson

>>> 's, developing a mouse model that contained the faulty and normal genes

>>> for

>>> alpha-synuclein, and conducting the experiments that led to their

>>> current

>>> findings.

>>>

>>> With evidence that this approach could be effective in treating Lewy

>>> Body

>>> disease, the UCSD researchers are now working with Elan Pharmaceuticals

>>> to

>>> develop alternative ways to produce alpha-synuclein antibodies, with the

>>> goal of making a vaccine that is safe and effective in humans. While

>>> this

>>> research could take many years and holds no promise of prevention or

>>> cure,

>>> the researchers are hopeful that the mouse studies are a step in the

>>> right

>>> direction.

>>>

>>> " This shows the first demonstration of a vaccine for this family of

>>> disease, " Masliah said.

>>>

>>> Co-authors of the paper are Rockenstein, Adame,

>>> Alford, Crews and Makoto Hashimoto, at UCSD, and Seubert,

>>> Lee, Goldstein, Tamie Chilcote, Dora Games, and Dale

>>> Schenk,

>>> at Elan.

>>>

>>> The research was supported by grants from Elan and the National

> Institute of

>>> Aging.

>>>

>>> Source: UCSD

>>>

>>>

>>> ________________________________

>>>

[Guest guest]

Some pesticides are also associated with Parkinson's disease.

Re: A Vaccine Approach To Treating Parkinson's

> Disease

>

>

> > Yes, homeopathy treats the whole person and all of their symptoms

> > including

> > Parkinson's

> > Some drugs cause parkinson's like symptoms and also coffee

> >

> > At 08:48 AM 6/18/2005 -0400, you wrote:

> >>I have a friend with early adult onset parkinson's - she is 38 yrs

> >>old. Does homeopathy treat parkinson's?

> >>

> >>~~ Jacqui

> >>

> >>

> >>

> >>On 6/17/05, Mum2mishka <mum2mishka@...> wrote:

> >>> http://www.medi-news.com/article2427.html

> >>>

> >>> A Vaccine Approach To Treating Parkinson's Disease

> >>>

> >>> Researchers at the UCSD School of Medicine working with scientists at

> >>> Elan

> >>> Pharmaceuticals, have reported promising results in mice of a vaccine

> >>> approach to treating Parkinson's and similar diseases. These results

> >>> appear

> >>> in the June edition of the journal Neuron.

> >>>

> >>> Dr. Eliezer Masliah, Professor of Neurosciences and Pathology at UCSD,

> >>> and

> >>> colleagues at UCSD and Elan Pharmaceuticals in San Francisco,

vaccinated

> >>> mice using a a combination of the protein that abnormally accumulates

in

> > the

> >>> brains of Parkinson's (called human alpha-synuclein) and an adjuvant.

> >>> This

> >>> approach resulted in the generation of anti-alpha synuclein antibodies

> >>> in

> >>> mice that are specially bred by Masliah's team to simulate Parkinson's

> >>> disease, resulting in reduced build-up of abnormal alpha-synuclein.

The

> >>> accumulation of abnormal alpha-synuclein is associated with

degeneration

> >>> of

> >>> nerve cells and interference with normal inter-cellular communication,

> >>> leading to Parkinson's disease and dementia.

> >>>

> >>> The work marks the first time a vaccine for this family of diseases

has

> > been

> >>> found effective in animal studies. Scientists at Elan Pharmaceuticals

> >>> have

> >>> been working for the past few years in a vaccine for Alzheimer's

> >>> Disease.

> >>>

> >>> The researchers focused on a spectrum of neurological disorders called

> >>> Lewy

> >>> body disease, which include Parkinson's and Alzheimer's. These

disorders

> > are

> >>> marked by the presence of Lewy bodies -- abnormal clumps of

> >>> alpha-synuclein -- in the brain. Normally, alpha-synuclein proteins

> >>> support

> >>> communications between brain cells, or neurons. However, when abnormal

> >>> proteins clump together in the neurons, a build-up of synuclein can

cut

> >>> off

> >>> neuron activity, blocking normal signaling between brain cells and

> >>> ultimately choking the cells to death.

> >>>

> >>> " We found that the antibodies produced by the vaccinated mice

recognized

> > and

> >>> reduced only the abnormal form of alpha-synuclein, since the protein's

> >>> normal form is in a cellular compartment where antibodies can't reach

> >>> it, "

> >>> said Masliah. " Abnormal alpha-synuclein finds its way to the cell

> >>> membrane,

> >>> where antibodies can recognize it. "

> >>>

> >>> Masliah stressed that the team's experimental active immunization,

while

> >>> effective in mice, may not be as useful in humans. " We would not want

to

> >>> actively immunize humans in this way by triggering antibody

development,

> >>> because one could create harmful inflammation, " he cautioned.

" However,

> >>> it

> >>> might be feasible to inject antibodies directly, as if the patient

were

> >>> creating his or her own. "

> >>>

> >>> The team, the first to identify the presence of these proteins in the

> >>> human

> >>> brain, originally thought the protein played an important role in the

> >>> development of Alzheimer's disease. Then, an explosion of research

> >>> linked

> >>> Lewy bodies and their constituent proteins to both Alzheimer's and

> > Parkinson

> >>> 's. The team spent four years clarifying alpha-synuclein's role in

> > Parkinson

> >>> 's, developing a mouse model that contained the faulty and normal

genes

> >>> for

> >>> alpha-synuclein, and conducting the experiments that led to their

> >>> current

> >>> findings.

> >>>

> >>> With evidence that this approach could be effective in treating Lewy

> >>> Body

> >>> disease, the UCSD researchers are now working with Elan

Pharmaceuticals

> >>> to

> >>> develop alternative ways to produce alpha-synuclein antibodies, with

the

> >>> goal of making a vaccine that is safe and effective in humans. While

> >>> this

> >>> research could take many years and holds no promise of prevention or

> >>> cure,

> >>> the researchers are hopeful that the mouse studies are a step in the

> >>> right

> >>> direction.

> >>>

> >>> " This shows the first demonstration of a vaccine for this family of

> >>> disease, " Masliah said.

> >>>

> >>> Co-authors of the paper are Rockenstein, Adame,

> >>> Alford, Crews and Makoto Hashimoto, at UCSD, and Seubert,

> >>> Lee, Goldstein, Tamie Chilcote, Dora Games, and Dale

> >>> Schenk,

> >>> at Elan.

> >>>

> >>> The research was supported by grants from Elan and the National

> > Institute of

> >>> Aging.

> >>>

> >>> Source: UCSD

> >>>

> >>>

> >>> ________________________________

> >>>